Dr. Zhang comes to Insilico with over two decades of experience in oncology clinical development, spanning across academia, biotechnology, and the pharmaceutical industry. Her most recent position as Global Clinical Development Program Leader at Bristol Myers Squibb (BMS) saw her at the forefront of late-stage oncology, managing critical global development strategies for various solid tumor indications. During her tenure at BMS, she successfully navigated the complexities of drug development across diseases including lung, breast, melanoma, gastric, colorectal, bladder, and head and neck cancers. Her extensive repertoire also covers diverse therapeutic modalities such as immuno-oncology approaches, targeted small-molecule therapies, and antibody-drug conjugates.

Dr. Zhang’s journey has been characterized by her ability to integrate scientific rigor and operational efficiency into clinical programs while ensuring close collaboration with global regulatory authorities. This has allowed her to guide development strategies that optimize study designs and support regulatory submissions successfully. Her history of building high-functioning clinical development organizations demonstrates her capacity to lead multidisciplinary teams while driving the culture of accountability and scientific excellence in clinical settings.

Before her time at BMS, Dr. Zhang held senior clinical development leadership roles at Infinity Pharmaceuticals and BioMed Valley Discoveries. Her career began with academic research and clinical operations at Harvard Medical School, a launchpad where she spearheaded NIH-sponsored clinical trials. With a PhD in Medicine and an MSc in Immunology and Microbiology from the University of Birmingham, along with a BSc in Nursing from the University of Portsmouth, Dr. Zhang is exceptionally equipped to tackle the complexities inherent in oncology drug development.

In her new position at Insilico, Dr. Zhang will be instrumental in orchestrating the clinical development strategy for the company’s oncology portfolio, which encompasses both early- and late-stage programs. Her role will not only involve leading clinical development efforts but also contributing to broader portfolio planning and the growth strategy of Insilico. Dr. Zhang will work cross-functionally, aligning closely with discovery, translational, biomarker, regulatory, and clinical operations teams to hasten development timelines and ensure the delivery of patient-centered therapies that differentiate themselves in the competitive landscape of oncology.

Her excitement about the role emanates from Insilico’s commitment to leveraging its unique AI-driven platform in oncology medicine development. The innovative drug discovery paradigms proposed by Insilico create a fertile environment for rethinking traditional approaches to oncology. The integration of advanced AI technologies fundamentally changes the landscape of drug discovery, enabling researchers to work with unparalleled efficiency. This is evident from Insilico’s recent progress across its oncology pipelines, with several innovative therapies advancing to Phase I clinical trials.

In 2025, milestones highlighting Insilico’s innovative capabilities included the announcement of ISM6331, a groundbreaking pan-TEAD inhibitor, completing its first patient dosing during a global, multicenter Phase I clinical trial aimed at combating mesothelioma and other solid tumors. The company also reported the progress of ISM3412, a KIF18A small-molecule inhibitor anticipated to obtain “best-in-class” status, marking a significant move forward with its first patient dosing announcement for treating locally advanced and metastatic solid tumors.

Insilico has adeptly entered numerous partnerships to enhance its pipeline. A notable collaboration with Servier, valued up to USD $888 million, exemplifies the company’s initiative to leverage its cutting-edge AI platform in the generation of first-in-class cancer therapies. Moreover, working closely with Menarini Group, Insilico secured important milestone payments as the collaboration continues to yield promising therapeutic candidates, reflective of the enhanced efficiency in drug development that is characteristic of Insilico’s methodologies.

Over the years, Insilico has drastically minimized the timeline usually required for preclinical drug development. Traditionally, early-stage drug discovery necessitates a 3 to 6-year effort; however, from 2021 to 2024, the company successfully nominated 20 preclinical candidates achieving a remarkable turnaround of merely 12 to 18 months per project. This achievement involved synthesizing and testing between 60 to 200 molecules within each program, showcasing Insilico’s impressive capacity to drive innovation in biopharmaceuticals.

Dr. Zhang’s arrival is not just a strategic hire; it symbolizes Insilico’s commitment to enhancing its capabilities and fulfilling its transformative vision for the future of oncology treatment. Her recognition as a leader in the field underscores the importance of experienced professionals who can bridge the gap between scientific research and clinical viability. Her strategic judgment and operational excellence are echoed praises from the company’s founder, Dr. Alex Zhavoronkov, who emphasizes her critical role in evolving Insilico’s AI-driven pipeline and delivering innovative therapies that align with patient needs.

As the landscape of cancer treatments continues to evolve, companies like Insilico Medicine are pausing to evaluate their methodologies, embracing the potential of AI, and prioritizing patient-centered approaches in their research and development processes. Dr. Zhang’s leadership brings with it the promise of strategic, scientifically advanced, and patient-focused solutions in the fight against cancer.

In summary, Insilico Medicine is poised to redefine the oncology space under Dr. Zhang’s guidance, as the company harnesses AI innovations to navigate the complexities of cancer pharmaceuticals. The firm’s bold, science-first culture paired with a committed leadership team nurtures an environment primed for groundbreaking advancements in drug development, ultimately aiming to meet the pressing needs of patients affected by cancer.

Subject of Research: Oncology Clinical Development
Article Title: Insilico Medicine Appoints Dr. Halle Zhang as Vice President of Clinical Development – Oncology
News Publication Date: February 6, 2026
Web References: Insilico Medicine
References: N/A
Image Credits: Insilico Medicine

Keywords

Health and medicine, Immunology, Pharmaceuticals, Clinical medicine, Biomedical engineering

Cancer stem cells are unique cellular entities that possess the capability to self-renew and differentiate into various cell types, spurring the heterogeneous population of tumor cells. This property makes them central to the development and progression of tumors, as well as to treatment resistance and relapse. The recent findings presented in this study suggest that these CSCs are not merely passengers in tumor development but rather active participants that shape the dynamics of their microenvironment.

A pivotal aspect of this research is the comprehensive genomic profiling of CSCs, which has revealed an array of mutations and epigenetic changes that distinguish them from their differentiated progeny. These alterations contribute significantly to the aggressiveness of tumors and are linked to the CSCs’ ability to evade conventional therapies. Understanding these genomic landscapes is crucial for devising effective treatment strategies that specifically target these resilient cells.

Moreover, the tumor microenvironment plays a significant role in modulating the behavior of CSCs. The study highlights the complex interactions between CSCs and various cell types, including stromal cells, immune cells, and extracellular matrix components. These interactions not only support the survival and proliferation of CSCs but also influence their ability to metastasize to distant sites in the body.

The findings of this study underscore the importance of targeting not just the tumor cells but the entire ecosystem within the tumor microenvironment. This holistic approach may lead to the development of novel therapies that excel beyond traditional methods that often fail due to the adaptive capacity of CSCs. Therapies designed to disrupt the supportive interactions and signals within the tumor microenvironment could prove essential in overcoming therapeutic resistance.

In addition, the study explores various therapeutics that are being investigated for their effectiveness against CSCs, including monoclonal antibodies, small molecule inhibitors, and immunotherapies. By delineating the molecular pathways involved in CSC maintenance and proliferation, this research sets the stage for the identification of biomarkers that could help predict patient responses to these treatments.

An important consideration in developing therapies targeting CSCs is the issue of heterogeneity. Tumors are characterized by a diverse population of cells, and not all CSCs exhibit the same genomic characteristics. This heterogeneity must be factored into therapeutic design to ensure that treatments are effective across varying tumor subtypes. The study suggests that personalized medicine approaches, utilizing detailed genomic and proteomic profiling, may be crucial in tailoring therapies to individual patients.

Furthermore, the research emphasizes the potential of leveraging novel delivery systems that could effectively target CSCs while minimizing off-target effects on normal tissues. Nanoparticles and other advanced drug delivery technologies could be optimized to deliver cytotoxic agents directly to CSCs, enhancing the efficacy and safety of treatment regimens.

Understanding the role of the immune system within the tumor microenvironment is another vital point raised in this research. The immune landscape surrounding tumors can either support CSC survival or trigger their destruction. By deciphering how CSCs interact with immune cells, researchers can explore more effective immunotherapies that enhance the body’s natural defenses against cancer.

The study also highlights the promise of combining therapies that target both CSCs and the tumor microenvironment. Synergistic approaches that utilize conventional chemotherapy alongside agents that specifically eradicate CSCs could offer a dual attack against tumors, potentially reducing the likelihood of relapse and treatment failure. The integration of these strategies may well represent the future of cancer treatment.

This comprehensive investigation into genomic landscapes and therapeutic perspectives of cancer stem cells not only advances our understanding of tumor biology but also opens up exciting avenues for future research. As outlined by the authors, continued exploration into the intersection of genetics, tumor microenvironment interactions, and treatment modalities will be essential to make significant strides in cancer therapy.

As researchers delve deeper into the complexities of cancer stem cells and their environments, the hope is that innovative treatment options will emerge, providing better outcomes for patients battling this formidable disease. The findings of Shrestha et al. herald a new era in the quest for effective cancer therapies that address the challenges posed by the resilient and elusive nature of cancer stem cells.

In summary, this pivotal study is a significant contribution to the cancer research field. It not only reviews existing knowledge of cancer stem cell biology but also emphasizes the critical need for a multifaceted approach to combat cancer effectively. Equipped with these insights, the scientific community is better positioned to develop therapies that truly penetrate the core of cancer’s resilience and offer hope to patients worldwide.

Subject of Research: Genomic landscapes and therapeutic perspectives of cancer stem cells in the tumor microenvironment.

Article Title: Genomic landscapes and therapeutic perspectives of cancer stem cells in the tumor microenvironment.

Article References:
Shrestha, P., Lee, D., Giri, A. et al. Genomic landscapes and therapeutic perspectives of cancer stem cells in the tumor microenvironment. J. Pharm. Investig. (2025). https://doi.org/10.1007/s40005-025-00794-y

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s40005-025-00794-y

Keywords: cancer stem cells, tumor microenvironment, genomic landscapes, therapeutic perspectives, treatment resistance, personalized medicine, immunotherapy, drug delivery systems.

Mitochondria, often referred to as the powerhouses of the cell, do more than simply generate ATP through oxidative phosphorylation; they are also crucial players in regulating cellular metabolism and apoptosis. Within the realm of cancer, these organelles have emerged as critical determinants of tumor behavior. It is within mitochondria that cellular energy and metabolic regulation occur, and any dysfunctions in this organelle can lead to aberrant cellular activities, an attribute that many cancers exploit in their fight against therapies.

Mitophagy, the selective autophagic degradation of damaged or dysfunctional mitochondria, serves as a quality control mechanism essential for cellular homeostasis. The process is instrumental in various physiological and pathological contexts, particularly in cancer. Numerous studies indicate that cancer cells possess a heightened capacity for mitophagy, allowing them to maintain mitochondrial health and energy production, even amidst the cytotoxic assault of chemotherapy. This resilience poses a significant challenge to cancer treatment strategies, establishing a vital link between mitochondrial dynamics and therapeutic resistance.

The research conducted by Zhao et al. makes it apparent that mitochondrial dynamics, encompassing the processes of mitochondrial fusion and fission, are equally influential in determining the fate of cancer cells. These processes ensure the proper distribution of mitochondria throughout the cell and are vital for their function during rapid cellular proliferation, a hallmark of cancer. The mechanisms regulating these dynamics have garnered attention for their potential as therapeutic targets. Altering mitochondrial fission and fusion may provide a novel approach to sensitize cancer cells to existing therapies.

Interestingly, the study reveals that dysfunctional mitochondrial dynamics can initiate a cascade that enhances drug resistance. For instance, hyperfusion of mitochondria can lead to decreased mitophagy, contributing to the accumulation of damaged organelles. This accumulation not only compromises cellular metabolism but also triggers signaling pathways that promote survival and resistance against drugs. Understanding this relationship could revolutionize how oncologists approach treatment, emphasizing the importance of targeting mitochondrial functions alongside traditional therapies.

Moreover, the authors elucidate the signaling pathways involved in mitophagy regulation. Notably, the PINK1/Parkin pathway emerges as a crucial mediator of this selective autophagy. PINK1, a mitochondrial serine/threonine kinase, accumulates on the outer membrane of depolarized mitochondria and recruits Parkin, an E3 ubiquitin ligase, to facilitate the autophagic degradation of dysfunctional mitochondria. Disruptions to this pathway can render cancer cells resistant to treatment, suggesting that interventions aimed at restoring proper mitophagic function may enhance sensitivity to chemotherapeutics.

This newly discovered molecular interplay has significant implications not just for our understanding of cancer biology but also for clinical approaches to treatment. As resistance develops against standard therapies, largely due to mitochondrial adaptations, the stratification of patients based on mitochondrial function may soon become a cornerstone in personalized medicine. Developing biomarkers that reflect mitochondrial dynamics and mitophagy status could guide more tailored and effective treatment strategies, enhancing the efficacy of existing therapies.

Nonetheless, the journey from basic research to clinical application remains fraught with challenges. The complexity of mitochondrial biology within the context of cancer requires an integrative approach, linking findings from cellular studies to patient outcomes. Researchers must work collaboratively across disciplines to unravel these complexities, fostering innovations that could lead to groundbreaking therapies targeting mitochondrial pathways in cancer.

The study by Zhao et al. serves as a reminder of the importance of understanding the tumor microenvironment. Cancer cells often hijack the surrounding stroma, creating a supportive niche that can protect them from therapeutic agents. Mitochondria within this microenvironment may behave differently than those in non-cancerous cells, further complicating treatment outcomes. Thus, exploring how mitochondrial dynamics interplay with the tumor microenvironment presents yet another avenue for potential therapeutic breakthroughs.

In conclusion, Zhao and colleagues have initiated a compelling discourse on the dual roles of mitochondrial dynamics and mitophagy in cancer drug resistance. As we stand at the threshold of an exciting era in cancer research, targeting mitochondrial processes represents a promising frontier in the relentless fight against cancer. By deciphering these complex relationships, researchers and clinicians alike can aspire to construct more effective, innovative strategies that will ultimately enhance patient survival rates.

The world of oncology is evolving, and with it, the quest for identifying effective mechanisms to disrupt cancer’s intricate survival strategies. The findings discussed are a part of a growing body of literature that elucidates the pivotal role of mitochondria in shaping cancer behavior. Continued investigation in this area will undoubtedly unveil new therapeutic options, creating hope for improved cancer management in the future.

Ultimately, the intersection of mitochondrial biology and cancer therapy may hold the key to overcoming some of the most pressing challenges faced in oncology today. By embracing such multidimensional perspectives in cancer research, scientists can pave the way forward, transforming lives in profound ways. The commitment to understanding and harnessing these mechanisms shows great promise and is imperative for advancing cancer treatments in the years to come.

As researchers like Zhao, Ren, and Yuan advance our knowledge of cellular components and their implications in cancer, the future of oncology becomes brighter. Continuous exploration and innovation in this field promise not only to decode the mysteries of cancer but also to unveil new opportunities for effective interventions.

Conclusion: The intricate dance of mitochondria, their dynamics, and the fate of cancer cells encapsulates a critical aspect of cancer drug resistance. As we extend our understanding through dedicated research, the prospect of using this knowledge to influence treatment outcomes offers a beacon of hope for patients battling cancer in a world where effective therapies remain desperately needed.

Subject of Research: Mitochondrial dynamics, mitophagy, and cancer drug resistance.

Article Title: The molecular mechanisms of mitochondrial dynamics and mitophagy and their complex association with cancer drug resistance.

Article References:

Zhao, Z., Ren, Y., Yuan, M. et al. The molecular mechanisms of mitochondrial dynamics and mitophagy and their complex association with cancer drug resistance.
J Transl Med 23, 1047 (2025). https://doi.org/10.1186/s12967-025-07078-x

Image Credits: AI Generated

DOI:

Keywords: Mitochondrial Dynamics, Mitophagy, Cancer Drug Resistance, Oncology, Cancer Therapy, Personalized Medicine.

The research team, under the leadership of Kishore Guda, an associate professor at the Digestive Health Research Institute of Case Western Reserve’s School of Medicine, has unveiled the significant role of a special lincRNA named lincPRKD. This discovery opens the door to a new target for preventing and treating gastric cancer. Guda emphasized the potential of lincPRKD, stating its active role in both gastric and esophageal cancers. By gaining insight into how lincPRKD functions within gastric cancer pathways, researchers aspire to develop novel therapeutic strategies aimed at improving patient outcomes.

In addition to its critical role in cancer progression, RNA serves as an essential mediator between deoxyribonucleic acid (DNA) and protein synthesis, translating genetic instructions into functional proteins. Non-coding RNAs, including lincRNAs like lincPRKD, do not produce proteins but play vital regulatory roles in various biological processes, including gene expression modulation, cell growth, and differentiation. The implication of lincRNAs in tumorigenesis, particularly in gastric cancer, highlights an innovative direction for cancer research that warrants deeper investigation.

The extensive study conducted by Guda, along with senior research associate Durga Ravillah and assistant professor Andrew Blum, has recently been published in the journal Gastro Hep Advances. The study is pivotal not only for its findings but for its methodological approach, which seeks to clarify the prevalence of lincPRKD activation in gastric and esophageal cancers. The researchers aim to categorize tumor subgroups and assess whether the presence of lincPRKD correlates with any specific molecular characteristics, potentially identifying a new biomarker for early detection.

As the research progresses, the focus extends to the relationship between lincPRKD activation and therapeutic resistance. Many gastric and esophageal cancer patients encounter challenges with conventional treatments, including chemotherapy and radiation therapy, which often result in limited success. Guda expressed a strong commitment to understanding whether the resistance to these therapies is associated with the activation of lincRNAs, thereby seeking to provide patients with more tailored and effective treatment options. This inquiry reflects a broader trend in oncology toward personalized medicine, where treatments are designed around individual genetic and molecular profiles.

The research team has plans to cultivate cancer biopsy tissues obtained from patients in specially engineered immune-compromised mouse models. This innovative approach allows researchers to observe tumor growth in a controlled environment while assessing the therapeutic potential of targeting lincPRKD. Blocking the expression of lincPRKD may potentially halt the formation of malignant tumors, a strategy that could revolutionize treatment options by addressing the underlying molecular mechanisms of tumorigenesis.

In addition to the experimental studies currently underway, the researchers are also exploring the possibility of developing diagnostic tools that capitalize on the presence of lincPRKD in tissues from patients. Early detection of gastric cancer significantly improves survival rates; therefore, identifying lincPRKD as a detectable biomarker holds great promise for enhancing patient outcomes through timely intervention. The broader implications of this discovery could extend beyond gastric cancer, potentially influencing the understanding and treatment of other malignancies where lincRNAs are known to play a role.

The insights provided by this groundbreaking research present a formidable challenge to our existing understanding of gastric cancer biology and treatment. By connecting the dots between non-coding RNA activity and cancer progression, we not only unveil new pathways for therapeutic intervention but also encourage the scientific community to adopt a more nuanced approach to understanding cancer’s complex landscape. As researchers continue to unravel the complexities of RNA involvement in cancer, the hopeful prospect of more effective treatments looms on the horizon.

This research not only signifies a pivotal moment in gastric cancer studies but underscores the importance of continued investment in innovative biomedical research. As we grapple with the stark realities posed by cancer globally, every discovery propels us closer to unlocking potential cures and extending the lives of countless patients. Importantly, fostering collaboration within the scientific community remains vital as we collectively strive toward achieving these remarkable milestones in cancer research.

In conclusion, the promising findings regarding lincPRKD’s role in gastric cancer serve as a reminder of the potential hidden within non-coding RNAs. As researchers delve deeper into the intricacies of cancer biology, the hope is to translate these laboratory findings into clinical applications that could redefine the treatment landscape for gastric cancer and other malignancies. With continued exploration and innovative research, the future of cancer therapy remains filled with hope, guided by discoveries that one day may provide the answers that many have long sought.

Subject of Research: Non-coding RNAs in Gastric Cancer
Article Title: LincPRKD: A Long Intergenic Noncoding RNA Activated in Gastric Cancer
News Publication Date: January 16, 2025
Web References: Gastro Hep Advances
References: DOI: 10.1016/j.gastha.2025.100618
Image Credits: Case Western Reserve University

Keywords: Stomach cancer, lincRNA, gastric cancer, RNA research, cancer biomarkers

In response to these challenges, researchers from Waseda University have introduced a groundbreaking imaging technique that employs neutron activation to create a detectable radioisotope of gold. This advancement allows for long-term tracking of AuNPs within the body without the complications posed by external tracers. The study, spearheaded by Nanase Koshikawa, a PhD student at the Graduate School of Advanced Science and Engineering at Waseda University, along with her advisor Jun Kataoka and collaborators from Osaka University and Kyoto University, highlights a significant step forward in cancer treatment. The findings of this vital research are slated for publication in the highly regarded journal “Applied Physics Letters.”

Koshikawa explained the limitations of traditional imaging methods that rely on external tracers, stating the potential for detachment during circulation undermines the effectiveness of these techniques. By directly altering the AuNPs, the researchers have succeeded in making them detectable via X-rays and gamma rays without the need for external substances. This novel approach allows for more accurate readings of the nanoparticles’ movements and efficacy in drug delivery.

The mechanism behind the new imaging technique revolves around the activation of stable gold nanoparticles through neutron irradiation. The stable isotope, gold-197 (Au-197), is transformed into its radioactive counterpart, gold-198 (Au-198), which emits gamma rays detectable from outside the body. This groundbreaking transformation preserves the chemical properties of the gold yet allows researchers to visualize the AuNPs in real time. Kataoka expounded upon the and the use of neutron activation, emphasizing that altering the material through particle irradiation provides a clear view of its behavior inside living organisms.

In practical applications, the research team injected these radioactive AuNPs into tumor-bearing mice to demonstrate the effectiveness of their imaging system. By visualizing the nanoparticles in vivo, the researchers confirmed that the technique holds the promise for future clinical applications. Additionally, the researchers showcased how this imaging technique could be applied in the context of drug delivery, specifically with a radio-therapeutic drug known as astatine-211 (At-211), commonly used in targeted cancer therapies.

Astatine-211, with its short half-life of 7.2 hours, presents particular challenges for tracking, as its emitted X-rays dissipate quickly. In this study, the team cleverly labeled the At-211 with the AuNPs, thereby forming composite AuNPs labeled with Au-198. This labeling allows the imaging of drug distribution over an extended period, thanks to the longer half-life of Au-198, which stands at 2.7 days. This innovative combination overcomes the limitations posed by the short half-life of At-211, offering a solution for long-term imaging and tracking of treatment efficacy.

Kato, another co-author, discusses the implications of this research for cancer treatment, noting that the ability to track the distribution of drugs like At-211 enhances the potential for achieving targeted therapy. The study represents a crucial advancement in the realm of targeted drug delivery systems, paving the way for precise monitoring of the distribution and efficacy of medications within the body. With more effective tracking mechanisms in place, the efficiency of drug delivery systems is expected to improve significantly.

The research team envisions the future of this technology extending beyond merely tracking gold nanoparticles. They hope to refine their neutron activation imaging technique further, applying it to various nanoparticle-based systems to enhance imaging resolution. Co-author Yuichiro Kadonaga expressed aspirations to transform this innovative technique into a viable clinical application, thus revolutionizing the field of imaging technologies in medical contexts.

The study also emphasizes the wider implications of gold nanoparticles in medical applications. With ongoing research exploring various facets of nanotechnology, the team believes their work could catalyze significant advancements in the field of nanomedicine, particularly for cancer treatment. The simplicity and scalability of the imaging technique provide a foundation for future research to optimize gold-based nanomaterials for clinical use.

In summary, this breakthrough research offers hope for more effective cancer treatments through real-time visualization of nanoparticle behavior and drug distribution. As understanding deepens and technology evolves, the prospect of more advanced, targeted therapies becomes increasingly attainable. The collaborative efforts between Waseda University, Osaka University, and Kyoto University signal a crucial shift toward a future where drug delivery systems can be closely monitored, ensuring that treatments are not only effective but also personalized.

As researchers continue to explore the frontiers of nanotechnology within medicine, they remain committed to developing solutions that address current limitations in cancer treatment. By pioneering methodologies that enhance the monitoring of drug delivery systems, they are not only facilitating advancements in medical imaging but also providing a pathway to innovative cancer therapies with improved safety and efficacy. These efforts exemplify a commitment to transforming the prognosis for cancer patients around the world.

Through these innovations, it is clear that the future of targeted cancer therapy is bright, with promising possibilities that lie in the integration of advanced imaging techniques and the versatility of nanoparticles. As the researchers move forward, they do so with the intention of redefining the landscape of cancer treatment, emphasizing the role of technology in shaping effective, patient-centered therapies.

Subject of Research: Animals
Article Title: Activation imaging of gold nanoparticles for versatile drug visualization: an in vivo demonstration
News Publication Date: 12-Mar-2025
Web References: DOI link
References: None available
Image Credits: Nanase Koshikawa from Waseda University
Keywords: Gold nanoparticles, cancer therapy, drug delivery, imaging technique, neutron activation, in vivo tracking, radioactive isotopes, nanomedicine, therapeutic imaging, oncological research.